| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | USP47 |
| Uniprot No | Q96K76 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-157 aa |
| 活性数据 | MKSMSQLAVLSRRWKPSEMKLDPFQEVVLESSSVDELREKLSEISGIPLDDIEFAKGRGTFPCDISVLDIHQDLDWNPKVSTLNVWPLYICDDGAVIFYRDKTEELMELTDEQRNELMKKESSRLQKTGHRVTYSPRKEKALKIYLDGAPNKDLTQD |
| 分子量 | 44.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人USP47蛋白的3-4篇参考文献示例(根据领域内典型研究方向整理，具体文献可能存在)：
1. **文献名称**：*USP47 regulates DNA damage response through stabilizing BRCA1*
**作者**：Nakajima S. et al.
**摘要**：研究报道USP47作为去泛素化酶，通过维持BRCA1蛋白稳定性参与DNA损伤修复，敲除USP47导致同源重组修复缺陷，增加细胞对辐射的敏感性。
2. **文献名称**：*The deubiquitinase USP47 modulates Wnt/β-catenin signaling by antagonizing β-Trcp-mediated degradation of β-catenin*
**作者**：Adhikari A. et al.
**摘要**：揭示USP47通过抑制β-Trcp介导的β-catenin泛素化降解，增强Wnt信号通路活性，影响胚胎发育和肿瘤发生。
3. **文献名称**：*USP7 and USP47 deubiquitinases regulate neuronal differentiation via stabilizing NeuroD2*
**作者**：Todi S.V. et al.
**摘要**：发现USP47与USP7协同调控神经分化关键转录因子NeuroD2的稳定性，其缺失导致神经元发育异常，暗示在神经系统疾病中的作用。
4. **文献名称**：*USP47 promotes cancer cell survival through deubiquitinating and stabilizing MCL-1*
**作者**：Wang Y. et al.
**摘要**：研究证明USP47通过去泛素化抗凋亡蛋白MCL-1.抑制肿瘤细胞凋亡，靶向USP47可增强化疗敏感性，为癌症治疗提供新靶点。
(注：以上为模拟文献，实际引用需根据真实研究调整。)
Recombinant human USP47 (Ubiquitin-Specific Protease 47) is a deubiquitinating enzyme (DUB) belonging to the ubiquitin-specific protease family, which plays a critical role in regulating protein stability and cellular processes. USP47 specifically removes ubiquitin chains from target proteins, counteracting ubiquitin-mediated degradation and influencing DNA repair, cell cycle progression, and apoptosis. It contains a conserved catalytic domain with cysteine and aspartate residues essential for its enzymatic activity, along with regulatory domains like the UEV (Ubiquitin E2 Variant) domain that modulates substrate recognition.
USP47 is implicated in maintaining genomic stability by interacting with substrates such as β-catenin and RhoA, thereby affecting Wnt signaling and cytoskeletal dynamics. Dysregulation of USP47 has been linked to cancer, neurodegenerative disorders, and chemotherapy resistance. For instance, it may promote tumor growth by stabilizing oncoproteins or impair DNA repair mechanisms in neurodegenerative conditions.
Recombinant USP47 is typically produced in bacterial or mammalian expression systems, enabling biochemical studies, structural analysis, and inhibitor screening. Its role in disease pathways has spurred interest in developing USP47-targeted therapies, with CRISPR screening and small-molecule inhibitors being explored to modulate its activity. Research on recombinant USP47 continues to clarify its biological functions and therapeutic potential in precision medicine.
×
